• Coya Therapeutics outlined its lead program COYA 302, a low-dose IL-2 and CTLA4-Ig combination for ALS and frontotemporal dementia.
• Phase 2 ALSTARS ALS study active; enrollment expected 2H 2026; top-line data expected 1Q 2027; Fast Track designation noted.
• FTD program advanced with IND accepted 1Q 2026; Phase 2a start expected 2H 2026; ADDF backing includes USD 5 million.
• Cash runway estimated into 2H 2027; cash position cited at about USD 50.7 million as of March 31, 2026.
• Dr. Reddy’s partnership cited with royalties and up to about USD 700 million in milestones; includes a USD 10 million strategic investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.